MSF Accuses Gilead of Blocking Access to HIV Prevention Drug

The meeting room fell silent on 18 February 2026. Across the table, executives from Gilead Sciences delivered the same answer they’d given before: no direct sales of lenacapavir to Médecins Sans Frontières. The humanitarian organisation had come prepared with compelling arguments about global health equity. They left empty-handed once again.

Six weeks later, MSF’s frustration boiled over into public view. On 30 March, the medical charity published a scathing open letter accusing Gilead of prioritising profits over lives by refusing to sell the revolutionary HIV prevention drug directly to their programmes.

The Drug That Changes Everything

Lenacapavir represents a seismic shift in HIV prevention. Unlike daily pills that many struggle to take consistently, this injectable pre-exposure prophylaxis requires just two doses per year. Clinical trials show near-complete protection rates – a medical breakthrough for people facing barriers to daily medication regimens.

But access remains severely limited. Gilead currently channels lenacapavir through the Global Fund to Fight AIDS, Tuberculosis and Malaria, providing enough doses for 2 million people over three years in low- and middle-income countries. Only a handful of the 18 eligible countries have received supplies so far.

The Standoff Intensifies

MSF’s repeated requests for direct purchasing have met consistent refusal. The charity argues this stance is “unconscionable” given the drug’s development involved public funding and trials in countries now excluded from affordable access.

Gilead maintains its position that supply remains capped until generic versions become available in 2027. The company directs MSF to access doses through existing Global Fund channels, claiming no additional supply is available for direct sales.

Yet critics question this reasoning. Public Citizen, a consumer advocacy group, argues the refusal appears designed to favour sales in wealthier markets over humanitarian need.

The dispute highlights a familiar tension in global health. With close to 1.3 million new HIV infections occurring worldwide each year, access to prevention tools can mean the difference between life and death for vulnerable populations.

MSF has requested an urgent follow-up meeting with Gilead by 13 April 2026. The charity’s public campaign suggests private diplomacy has reached its limits.

The controversy highlights broader questions about pharmaceutical pricing and global health equity. As lenacapavir’s potential becomes clearer, pressure will likely mount on Gilead to expand access beyond current channels.

Whether that pressure translates into policy change is unclear. For now, the standoff continues – with millions of lives hanging in the balance.

Key Takeaways

• MSF publicly accused Gilead of refusing direct sales of lenacapavir after private negotiations failed
• The twice-yearly injectable offers near-complete HIV prevention but access remains severely limited
• Current supply through Global Fund covers 2 million people over three years in eligible countries

What This Means for Kent Residents

This international dispute doesn’t affect HIV prevention services available locally in Kent. Lenacapavir is approved and accessible through the NHS for high-risk groups, while existing PrEP options remain available at sexual health clinics across the county. Kent residents concerned about HIV risk can contact their local sexual health service or call NHS 111 for guidance on prevention options, with services continuing without disruption regardless of global access debates.